Among the CCR5 inhibitors developed so far, maraviroc is the first drug that has been approved by the US FDA for treating patients with R5 HIV-1. Although many CXCR4 inhibitors, some of which are ...

But will inhibitors aimed at the CCR5 co-receptor force HIV-1 to evolve more virulent forms? Other targets for entry inhibitors include two co-receptors on the cell surface—CCR5 and CXCR4 ...

Computational analysis of the variations in the HIV-1 genome sequence that correlate with preferential binding to the CCR5 (C-C-motif receptor 5) or CXCR4 (C-X-C motif receptor 4) coreceptors in ...

CCR5-tropic virus is the predominant virus encountered, though CXCR4-tropic virus strains are more likely encountered, in patients with advanced HIV disease. Results from Phase III clinical trials ...

This image shows CCR5 side-by-side with alternate HIV co-receptor CXCR4. While the two share similar overall architecture, their binding pockets show important differences in shape and charge ...